Target intelligence / Profile preview

Son of sevenless homolog 1 (SOS1)–KRAS protein-protein interface (SOS1–KRAS interface)

Target
SOS1–KRAS interface
Molecular classification
Guanine nucleotide exchange factor, Protein-protein interface
01

Overview

Son of sevenless homolog 1 (SOS1) is a universal guanine nucleotide exchange factor (GEF) that facilitates the transition of RAS proteins, including KRAS, from an inactive GDP-bound state to an active GTP-bound state [UniProt: Q07889]. This activation is a critical step in the MAPK/ERK signaling pathway, which regulates fundamental cellular processes such as growth, differentiation, and survival [PubMed: 30633532]. The SOS1–KRAS protein-protein interface has become a high-priority therapeutic target because many cancers are driven by KRAS mutations that keep the protein in a constitutively active state. Small molecule inhibitors targeting this interface bind to SOS1 and prevent its interaction with KRAS, thereby inhibiting the nucleotide exchange process and reducing RAS-GTP levels [PubMed: 33468548]. This "mutation-agnostic" strategy is particularly valuable as it can potentially inhibit a broad range of KRAS variants, including G12D, G12V, and G12C, and may synergize with direct KRAS inhibitors to overcome adaptive resistance [ClinicalTrials.gov: NCT04111458].

Other names
SOS1-KRAS interaction siteSOS1 catalytic pocketSOS1-RAS interface
02

Mechanism of action

Inhibition of the protein-protein interaction between the GEF SOS1 and KRAS, which prevents the exchange of GDP for GTP, thereby maintaining KRAS in its inactive state and suppressing downstream MAPK signaling [PubMed: 30633532].

03

Biological functions

Signal transductionCell proliferationRAS activationMAPK/ERK pathway regulation
04

Disease associations

CancerNon-small cell lung cancerColorectal cancerPancreatic cancerNoonan syndrome
05

Safety considerations

Gastrointestinal toxicities (diarrhea, nausea)Skin rashFatiguePotential for compensatory activation of other RAS isoforms or SOS2 [PubMed: 33468548]
06

Interacting drugs

BI-1701963

3 more in the full profile.

07

Biomarkers

KRAS mutation status (e.g., G12C, G12D, G12V)SOS1 expression levelsPhosphorylated ERK (p-ERK) levels

Beyond the preview

Go deeper on Son of sevenless homolog 1 (SOS1)–KRAS protein-protein interface (SOS1–KRAS interface).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Son of sevenless homolog 1 (SOS1)–KRAS protein-protein interface (SOS1–KRAS interface).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call